Vertex, Inc.(VERX)Earnings, Financials & Key RatiosVertex, Inc. (VERX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
highlighted by a 2026Q1 operating loss of $3.0 million and a current ratio of 0.86, suggests that the current valuation of 284.25x TTM P/E is not supported by underlying cash generation.
Vertex, Inc. (VERX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Vertex, Inc. (VERX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.17vs $0.16+6.3% | $197Mvs $195M+0.9% |
| Q1 2026 | Feb 11, 2026 | $0.17vs $0.17+0.0% | $195Mvs $194M+0.2% |
| Q4 2025 | Nov 3, 2025 | $0.17vs $0.17+0.0% | $192Mvs $194M-1.1% |
| Q3 2025 | Aug 6, 2025 | $0.15vs $0.14+7.1% | $185Mvs $193M-4.3% |
Recent stock market news and headlines for Vertex, Inc. (VERX)
CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while maintaining a robust cash position. Vertex Pharmaceuticals offers a profitable portfolio anchored by cystic fibrosis treatments alongside expansion into gene therapy and pain management.
HOUSTON--(BUSINESS WIRE)-- #BaseOils--Vertex Energy, Inc. (“Vertex” or the “Company”) today announced it is advancing a project at its Mobile, Alabama refinery to produce crude-derived conventional Group III base oils through the Company's existing hydrocracker and related processing infrastructure, providing lubricant manufacturers and blenders with an additional domestic source of high-quality Group III supply. The project is designed to add an incremental 6,000 barrels per day of conventional Group III.
Vertex Pharmaceuticals Incorporated's R&D success extends beyond its cystic fibrosis franchise. VRTX's Povetacicept could be approved by the FDA as early as November 30th for the treatment of an autoimmune disease called immunoglobulin A nephropathy. On the other hand, despite the high commercial expectations for Journavx and Casgevy, demand remains soft.
This new end-to-end AI enablement release enables go-to-market and education teams to build hands-on AI content faster and experience it in real, production-like AI infrastructure. It represents a combination no other hands-on platform offers today.
Vertex Pharmaceuticals and Eli Lilly are both going after the non-opioid pain management market. Vertex Pharmaceuticals has a lead, but both drugmakers could be successful in this niche.
Key metrics vs top competitors for Vertex, Inc. (VERX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.40 | $2.17B | 335.00 | 12.25% | 0.96% | 3.29% | — | |
| $0.88 | $4.19M | -0.01 | -29.45% | -237.25% | -500.33% | — | |
| $41.58 | $5.39B | 88.47 | 21.28% | 4.17% | 10.77% | — | |
| $281.17 | $76.91B | 20.57 | 15.63% | 21.91% | 23.29% | — | |
| $245.60 | $98.89B | 24.61 | 7.07% | 20.12% | 68.69% | — | |
| $118.84 | $6.36B | 29.56 | 13.74% | 14.94% | 22.36% | — |
Vertex, Inc. (VERX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Vertex, Inc. (VERX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Apr 28, 2026·SEC
Feb 11, 2026·SEC
Get notified when VERX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Vertex, Inc. (VERX) stock FAQ — growth, dividends, profitability & financials explained
Vertex, Inc. (VERX) reported $768.0M in revenue for fiscal year 2025. This represents a 182% increase from $272.4M in 2018.
Vertex, Inc. (VERX) grew revenue by 12.2% over the past year. This is steady growth.
Vertex, Inc. (VERX) reported a net loss of $6.4M for fiscal year 2025.
Vertex, Inc. (VERX) has a return on equity (ROE) of 3.3%. This is below average, suggesting room for improvement.
Vertex, Inc. (VERX) generated $99.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
